The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1

  • MA Wainberg
    Lady Davis Institute for Medical Research, Sir Mortimer B. Davis, Jewis General Hospital, Montreal, Quebec, Canada.
  • A Dascal
    Lady Davis Institute for Medical Research, Sir Mortimer B. Davis, Jewis General Hospital, Montreal, Quebec, Canada.
  • N Blain
    Lady Davis Institute for Medical Research, Sir Mortimer B. Davis, Jewis General Hospital, Montreal, Quebec, Canada.
  • L Fitz-Gibbon
    Lady Davis Institute for Medical Research, Sir Mortimer B. Davis, Jewis General Hospital, Montreal, Quebec, Canada.
  • F Boulerice
    Lady Davis Institute for Medical Research, Sir Mortimer B. Davis, Jewis General Hospital, Montreal, Quebec, Canada.
  • K Numazaki
    Lady Davis Institute for Medical Research, Sir Mortimer B. Davis, Jewis General Hospital, Montreal, Quebec, Canada.
  • M Tremblay
    Lady Davis Institute for Medical Research, Sir Mortimer B. Davis, Jewis General Hospital, Montreal, Quebec, Canada.

書誌事項

公開日
1988-12-01
DOI
  • 10.1182/blood.v72.6.1904.1904
公開者
American Society of Hematology

この論文をさがす

説明

<jats:title>Abstract</jats:title> <jats:p>The effect of cyclosporine A (CyA) on the ability of the human immunodeficiency virus type 1 (HIV-1) to infect the H-9 T-cell leukemic line, as well as interleukin-2 (IL-2)-grown human peripheral blood- derived lymphocytes, has been studied. Pretreatment of H-9 cells and human lymphocytes with CyA over 24 hours completely prevented viral infection over a 21-day period, whereas the addition of drug at two hours postinfection with HIV-1 had a significant inhibitory effect on viral replication and expression of the virus-specific antigens p17 and p24. However, if CyA was added at later times to these lymphocytic cells, this inhibitory effect was lost. Indeed, the removal of CyA from cultures that had been treated from two hours after infection led to the rapid production of progeny virus. HIV-1 was able to infect peripheral blood lymphocytes obtained from each of four kidney allograft recipients on long-term CyA antirejection therapy, as long as drug was not included in the culture medium. In addition, we asked what effect pretreatment with CyA of cells of the U-937 monocytic line and primary cultures of human monocytes/macrophages might have on infection by HIV-1. CyA had no demonstrable effect on the ability of HIV-1 to infect cells of either type.</jats:p>

収録刊行物

  • Blood

    Blood 72 (6), 1904-1910, 1988-12-01

    American Society of Hematology

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ